87 related articles for article (PubMed ID: 1728409)
1. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.
Sung C; Shockley TR; Morrison PF; Dvorak HF; Yarmush ML; Dedrick RL
Cancer Res; 1992 Jan; 52(2):377-84. PubMed ID: 1728409
[TBL] [Abstract][Full Text] [Related]
2. Altered biodistribution of indium-111-labeled monoclonal antibody 96.5 to tumors and normal tissues of nude mice bearing human melanoma xenografts in visceral organs.
McCready DR; Price J; Balch CM; Murray JL
Cancer Immunol Immunother; 1989; 30(5):257-61. PubMed ID: 2624918
[TBL] [Abstract][Full Text] [Related]
3. High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts.
Wahl RL; Wilson BS; Liebert M; Beierwaltes WH
Cancer Immunol Immunother; 1987; 24(3):221-4. PubMed ID: 3594484
[TBL] [Abstract][Full Text] [Related]
4. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study.
Blumenthal RD; Fand I; Sharkey RM; Boerman OC; Kashi R; Goldenberg DM
Cancer Immunol Immunother; 1991; 33(6):351-8. PubMed ID: 1652355
[TBL] [Abstract][Full Text] [Related]
5. Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis.
Chang HY; Wu S; Li Y; Zhang W; Burrell M; Webster CI; Shah DK
MAbs; 2021; 13(1):1874121. PubMed ID: 33499723
[TBL] [Abstract][Full Text] [Related]
6. Criteria for selecting monoclonal antibodies with respect to accumulation in melanoma tissue.
Matzku S; Brüggen J; Bröcker EB; Sorg C
Cancer Immunol Immunother; 1987; 24(2):151-7. PubMed ID: 3829049
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody uptake in B-cell lymphomas: experimental studies in nude mouse xenografts.
Schmid J; Möller P; Moldenhauer G; Dörken B; Bihl H; Matzku S
Cancer Immunol Immunother; 1993; 36(4):274-80. PubMed ID: 7679951
[TBL] [Abstract][Full Text] [Related]
8. Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies.
Ballou B; Fisher GW; Waggoner AS; Farkas DL; Reiland JM; Jaffe R; Mujumdar RB; Mujumdar SR; Hakala TR
Cancer Immunol Immunother; 1995 Oct; 41(4):257-63. PubMed ID: 7489569
[TBL] [Abstract][Full Text] [Related]
9. Stereo-selective binding of monoclonal antibodies to the poly-γ-D-glutamic acid capsular antigen of Bacillus anthracis.
Hubbard MA; Thorkildson P; Welch WH; Kozel TR
Mol Immunol; 2013 Oct; 55(3-4):337-44. PubMed ID: 23602451
[TBL] [Abstract][Full Text] [Related]
10. A compartment model for subcutaneous injection of monoclonal antibodies.
Zhong X; Liu Y; Ardekani AM
Int J Pharm; 2024 Jan; 650():123687. PubMed ID: 38103705
[TBL] [Abstract][Full Text] [Related]
11. Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice.
Liu S; Humphreys SC; Cook KD; Conner KP; Correia AR; Jacobitz AW; Yang M; Primack R; Soto M; Padaki R; Lubomirski M; Smith R; Mock M; Thomas VA
MAbs; 2023; 15(1):2263926. PubMed ID: 37824334
[TBL] [Abstract][Full Text] [Related]
12. A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate.
Casalini P; Caldera M; Canevari S; Ménard S; Mezzanzanica D; Tosi E; Gadina M; Colnaghi MI
Cancer Immunol Immunother; 1993 Jul; 37(1):54-60. PubMed ID: 8099847
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
Campoli M; Ferris R; Ferrone S; Wang X
Clin Cancer Res; 2010 Jan; 16(1):11-20. PubMed ID: 20028761
[TBL] [Abstract][Full Text] [Related]
14. Modeling multi-needle injection into solid tumor.
Subbotin V; Fiksel G
Am J Cancer Res; 2019; 9(10):2209-2215. PubMed ID: 31720083
[TBL] [Abstract][Full Text] [Related]
15. Selection, characterization and in vivo evaluation of novel CD44v6-targeting antibodies for targeted molecular radiotherapy.
Mortensen ACL; Berglund H; Segerström L; Walle M; Hofström C; Persson H; Nygren PÅ; Nilvebrant J; Frejd FY; Nestor M
Sci Rep; 2023 Nov; 13(1):20648. PubMed ID: 38001360
[TBL] [Abstract][Full Text] [Related]
16. Ab locks for improving the selectivity and safety of antibody drugs.
Lin WW; Lu YC; Chuang CH; Cheng TL
J Biomed Sci; 2020 Jun; 27(1):76. PubMed ID: 32586313
[TBL] [Abstract][Full Text] [Related]
17. Mechanistically Weighted Metric to Predict In Vivo Antibody-Receptor Occupancy: An Analytical Approach.
Khera E; Kim J; Stein A; Ratanapanichkich M; Thurber GM
J Pharmacol Exp Ther; 2023 Oct; 387(1):78-91. PubMed ID: 37105581
[TBL] [Abstract][Full Text] [Related]
18. Comparative Thermodynamics of the Reversible Self-Association of Therapeutic mAbs Reveal Opposing Roles for Linked Proton- and Ion-Binding Events.
Hopkins MM; Antonopoulos IH; Parupudi A; Bee JS; Bain DL
Pharm Res; 2023 Jun; 40(6):1383-1397. PubMed ID: 36869246
[TBL] [Abstract][Full Text] [Related]
19. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
Thurber GM; Schmidt MM; Wittrup KD
Adv Drug Deliv Rev; 2008 Sep; 60(12):1421-34. PubMed ID: 18541331
[TBL] [Abstract][Full Text] [Related]
20. Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning.
Makowski EK; Wang T; Zupancic JM; Huang J; Wu L; Schardt JS; De Groot AS; Elkins SL; Martin WD; Tessier PM
Nat Biomed Eng; 2024 Jan; 8(1):45-56. PubMed ID: 37666923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
